glycyl-arginyl-glycyl-aspartyl-seryl-proline has been researched along with fradafiban in 1 studies
| Studies (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Trials (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Recent Studies (post-2010) (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Studies (fradafiban) | Trials (fradafiban) | Recent Studies (post-2010) (fradafiban) |
|---|---|---|---|---|---|
| 162 | 1 | 20 | 8 | 5 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bode, C; Kohler, B; Kübler, W; Moser, M; Nordt, T; Peter, K; Salbach, P; Schwarz, M; Ylänne, J | 1 |
1 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-seryl-proline and fradafiban
| Article | Year |
|---|---|
Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Aspirin; Binding, Competitive; Biphenyl Compounds; CHO Cells; Cricetinae; Disintegrins; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Indomethacin; Mice; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Pyrrolidines; Recombinant Fusion Proteins | 1998 |